Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.83 |
| ▸ | MAPT | P10636 | 10/20 | 0.81 |
| ▸ | MEN1 | O00255 | 7/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.61 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15457559 | 0.94 | ALDH1A1 (0.76) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL189705 | 0.90 | MAPT (1.00) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL30514599 | 0.85 | KDM4E (0.72) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL189298 | 0.85 | KDM4E (0.72) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL190236 | 0.85 | KDM4E (0.71) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL14052923 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL16091771 | 0.78 | RXFP1 (0.76) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL10044528 | 0.77 | RXFP1 (1.00) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL14052839 | 0.77 | ALDH1A1 (0.65) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL24074827 | 0.76 | KDM4E (1.00) | ALDH1A1MAPTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-8765793-B2 | Compositions with skin benefit compounds and chelator stabilized cationic ammonium compounds | CONOPCO, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4075/4885MAPT 4580/4885MEN1 1310/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4075/4885MAPT 4580/4885MEN1 1310/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4089/4885MAPT 4606/4885MEN1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.